Ontunisertib

Ontunisertib
Clinical data
Other names	AGMB-129
Identifiers
	IUPAC name N-[(2,6-difluorophenyl)methyl]-2-[3-(6-methyl-2-pyridinyl)-4-quinolin-4-ylpyrazol-1-yl]acetamide;
CAS Number	2647949-48-0;
PubChem CID	156744887;
IUPHAR/BPS	13846;
ChemSpider	133323111;
UNII	SF6HGC94LK;
KEGG	D13315;
Chemical and physical data
Formula	C27H21F2N5O
Molar mass	469.496 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=NC(=CC=C1)C2=NN(C=C2C3=CC=NC4=CC=CC=C34)CC(=O)NCC5=C(C=CC=C5F)F;
	InChI InChI=InChI=1S/C27H21F2N5O/c1-17-6-4-11-25(32-17)27-21(18-12-13-30-24-10-3-2-7-19(18)24)15-34(33-27)16-26(35)31-14-20-22(28)8-5-9-23(20)29/h2-13,15H,14,16H2,1H3,(H,31,35); Key:QGXRIRYULXOGDQ-UHFFFAOYSA-N;

Ontunisertib is an investigational new drug that is being evaluated by Agomab Spain S.L.U. for the treatment of fibrostenotic Crohn's Disease. It is a TGF beta receptor 1 (ALK5) antagonist.^[1]^[2]

References

↑ "Ontunisertib - AgomAb Therapeutics". AdisInsight. Springer Nature Switzerland AG.
↑ Honap S, Dignass A, Jairath V, Danese S, Magro F, Peyrin-Biroulet L (June 2026). "Anti-fibrotic therapy in Crohn's disease: hype or reality-can intestinal fibrosis be targeted effectively?". Expert Review of Gastroenterology & Hepatology: 1–5. doi:10.1080/17474124.2026.2695461. PMID 42364152.